4 Questions About GLP-1s for Healthcare, Policy Leaders To Consider
As public and private payers decide whether to provide reimbursement for popular weight-loss drugs in the class known as glucagon-like peptide-1 receptor agonists, or GLP-1s, there are four key questions to consider.
CMS Proposes New Medicare Payment Models Aimed at Lowering Drug Prices
The Centers for Medicare and Medicaid Services has proposed limited implementation of two new Medicare payment models aimed at bringing domestic drug prices down and making them comparable with those of peer countries.
ACHI President, Other Arkansas Experts Discuss Rural Health Transformation Program
ACHI President and CEO Craig Wilson and other experts discuss the federal Rural Health Transformation Program and its potential impacts on Arkansas in the latest issue of the Journal of the Arkansas Medical Society.
Trump Administration Announces New Voluntary Payment Model for Weight-Loss Drugs
The Trump administration has announced plans for a new voluntary payment model intended to increase access to GLP-1 drugs — a class of medications often used for weight loss and the treatment of diabetes and other chronic conditions — for certain Medicare and Medicaid beneficiaries.
State, Federal Health Policy Changes Set To Take Effect in 2026
In this blog post, we highlight several new state and federal health laws that will take effect in 2026 — bringing changes to coverage requirements, preventive services, and healthcare financing and delivery systems.
Tracking Respiratory Illness Trends, Vaccination Rates as Winter Approaches
As winter draws near, this is a good time to take precautions against respiratory illnesses. Cases of flu and respiratory syncytial virus (RSV) activity are rising in the region, and Arkansas has experienced a higher number of cases of whooping cough this year than it has in over a decade.
